Pemphigus Vulgaris Market Will Expand in the Coming Decade as Per Report

Overview

Market Research Future (MRFR) has announced the launch of a new research report on the global pemphigus vulgaris market. The report uses detailed information about the market’s present and past movement to present valid forecasts about the market’s likely growth trajectory over the forecast period (2018-2027).

According to the report, the global pemphigus vulgaris market size was valued at USD 289.3 million in 2017 and is likely to rise to a valuation of USD 677.99 million by 2027 at an 8% CAGR through the forecast period.

On the other hand, the potential hazards of pemphigus vulgaris medication can be a major restraint against the global pemphigus vulgaris market. While corticosteroids and immunosuppressants are powerful medications that are highly effective in treating pemphigus vulgaris, they are also highly bioactive compounds that can have other effects in the body.

The use of corticosteroids, in particular, has been linked with an increased risk of osteoporosis, diabetes, increased weight, abnormal liver function, cataracts, myopathy, and fungal and viral infections.

Segmentation
The global pemphigus vulgaris market is segmented on the basis of treatment, route of administration, end-use, and region.

By treatment type, the pemphigus vulgaris market is segmented into corticosteroids, immunosuppressants, biological therapies, and intravenous immunoglobulin (IVIG) therapy.

By route of administration, the market is segmented into intravenous, subcutaneous, and oral. Intravenous administration is the most popular route of administration of pemphigus vulgaris drugs, followed by subcutaneous administration. The two segments accounted for 40.6% and 32.8% of the global pemphigus vulgaris market, respectively in 2017.

By end-use, the market is segmented into hospitals and clinics, specialty dermatology clinics, and research and academic laboratories.

Competitive Analysis
Leading players in the global pemphigus vulgaris market include Syntimmune (India), Janssen Global Services LLC (U.S.), Argenx SE (Belgium), Sanofi (France), Novartis AG (Switzerland), Pfizer Inc. (U.S.), Almirall SA (Spain), Biogen Inc. (U.S.), F. Hoffman-La Roche (Switzerland), and Principia Biopharma (U.S.).

https://www.marketresearchfuture.com/reports/pemphigus-vulgaris-market-6870